Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date

Kristen M Beck, Isabelle M Sanchez, Eric J Yang, Wilson Liao Department of Dermatology, University of California San Francisco, San Francisco, CA, USA Abstract: Plaque psoriasis is an immune-mediated skin disease that affects roughly 3% of adults in the United States. Advances over the past 20 years...

Full description

Bibliographic Details
Main Authors: Beck KM, Sanchez IM, Yang EJ, Liao W
Format: Article
Language:English
Published: Dove Medical Press 2018-08-01
Series:Psoriasis : Targets and Therapy
Subjects:
tildrakizumab
IL-23
IL-23p19
biologics
psoriasis
Online Access:https://www.dovepress.com/profile-of-tildrakizumab-asmn-in-the-treatment-of-moderate-to-severe-p-peer-reviewed-article-PTT

Internet

https://www.dovepress.com/profile-of-tildrakizumab-asmn-in-the-treatment-of-moderate-to-severe-p-peer-reviewed-article-PTT

Similar Items